NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

Show other versions (1)

Detalhes bibliográficos
Main Authors:	Seed, M, Betteridge, J, Caslake, M, Cooper, J, Humphries, S, Neil, A
Formato:	Journal article
Publicado em:	2009

Registos relacionados

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Por: Seed, M, et al.
Publicado em: (2009)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Por: Neil, A, et al.
Publicado em: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Por: Neil, H, et al.
Publicado em: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
Por: Neil, H, et al.
Publicado em: (2004)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
Por: Seed, M, et al.
Publicado em: (2011)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
Por: Humphries, SE, et al.
Publicado em: (2006)

Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
Por: A. David, et al.
Publicado em: (2023-12-01)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
Por: Humphries, SE, et al.
Publicado em: (2005)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Por: Neil, A, et al.
Publicado em: (2008)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
Por: J. Gratton, et al.
Publicado em: (2022-10-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
Por: Neil, A, et al.
Publicado em: (2008)

IN APPLICABILITY OF THE CARDIOVASCULAR RISK PREDICTOR "SCORE" TO PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH)
Por: Descamps, O, et al.
Publicado em: (2010)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
Por: S.E. Humphries, et al.
Publicado em: (2023-12-01)

Statins and familial hypercholesterolaemia.
Por: Neil, A, et al.
Publicado em: (2009)

How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused by the APOB p.(Arg3527Trp) variant in a South Asian family
Por: I. Tracey, et al.
Publicado em: (2022-10-01)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
Por: A. Rimbert, et al.
Publicado em: (2021-09-01)

A novel combinatorial non-viral vector to treat familial hypercholesterolaemia (FH)
Por: Kerr, A, et al.
Publicado em: (2016)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
Por: Neil, H, et al.
Publicado em: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
Por: Neil, H, et al.
Publicado em: (2005)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
Por: J. Gratton, et al.
Publicado em: (2023-12-01)

More evidence for inflammatory markers in predicting CHD risk
Por: Lyford Joanna, et al.
Publicado em: (2001-03-01)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
Por: Minhas, R, et al.
Publicado em: (2009)

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation
Por: P Sharma, et al.
Publicado em: (2012-03-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Por: Marks, et al.
Publicado em: (2000-01-01)

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care
Por: B. Iyen, et al.
Publicado em: (2021-09-01)

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records
Por: B. Iyen, et al.
Publicado em: (2022-10-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Por: Marks, D, et al.
Publicado em: (2000)

19. Using a novel combinatorial non-viral vector and small molecules to treat familial hypercholesterolaemia (FH)
Por: Kerr, A, et al.
Publicado em: (2016)

Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
Por: Ingunn Molven, et al.
Publicado em: (2013-01-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
Por: Marks, D, et al.
Publicado em: (2003)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
Por: Marks, D, et al.
Publicado em: (2002)

Familial hypercholesterolaemia
Por: D.J. Blom
Publicado em: (2011-01-01)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
Por: Marks, D, et al.
Publicado em: (2006)

The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)
Por: F. J. Kinnear, et al.
Publicado em: (2020-01-01)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
Por: Neil, H, et al.
Publicado em: (2000)

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
Por: E. Ofagbor, et al.
Publicado em: (2023-12-01)

Familial hypercholesterolaemia.
Por: Gill, P, et al.
Publicado em: (2012)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
Por: Neil, H, et al.
Publicado em: (2004)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
Por: Marks, D, et al.
Publicado em: (2003)

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records
Por: B. Iyen, et al.
Publicado em: (2021-09-01)